Kura Oncology Inc 2025年季度报告

FORM 10-Q(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) (I.R.S. Employer Identification No.) 12730 High Bluff Drive, Suite 400, San Diego, CA(Address of principal executive offices)(858) 500-8800(Registrant’s telephone number, including area code) Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required tofile such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for suchshorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of the close of business on April 28, 2025, the registrant had 86,574,687 shares of Common Stock, $0.0001 par value,outstanding. KURA ONCOLOGY, INC.TABLE OF CONTENTS Item 1. Condensed Financial Statements (unaudited)Condensed Balance Sheets−As of March 31, 2025 (unaudited) and December 31, 20241Condensed Statements of Operations and Comprehensive Loss – Three Months Ended March 31, 2025 and2024 (unaudited)2Condensed Statements of Stockholders’ Equity – Three Months Ended March 31, 2025 and 2024 (unaudited)3Condensed Statements of Cash Flows – Three Months Ended March 31, 2025 and 2024 (unaudited)4Notes to Condensed Financial Statements (unaudited)5Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations16Item 3. Quantitative and Qualitative Disclosures about Market Risk26Item 4. Controls and Procedures27PART II. OTHER INFORMATIONItem 1. Legal Proceedings28Item 1A. Risk Factors28Item 6. Exhibits76Signatures PART I. FINANCIAL INFORMATION KURA ONCOLOGY, INC.Condensed Balance Sheets(In thousands, except par value data) KURA ONCOLOGY, INC.Condensed Statements of Operations and Comprehensive Loss(In thousands, except per share data)(Unaudited) KURA ONCOLOGY, INC.Condensed Statements of Cash Flows(In thousands)(Unaudited) KURA ONCOLOGY, INC.Notes to Unaudited Condensed Financial Statements 1. Organization and Basis of Presentation Kura Oncology, Inc. is a clinical-stage biopharmaceutical company committed to realizing the promise ofprecision medicines for the treatment of cancer. Our pipeline consists of small molecule product candidatesdesigned to target cancer signaling pathways where there is a strong scientific and clinical rationale to improveoutcomes and, in general, we intend to pair our product candidates with molecular or cellular diagnostics toidentify those patients most likely to respond to treatment. We are conducting clinical trials of three productcandidates: ziftomenib, KO-2806 and tipifarnib. We also have additional programs that are at a discovery stage.We plan to advance our product candidates through a combination of internal development and strategicpartnerships while maintaining significant development and commercial rights. References in these Notes to Unaudited Condensed Financial Statements to the “Company,” “we,” “our” or “us,”refer to Kura Oncology, Inc. Basis of Presentation The accompanying unaudited condensed financial statements should be read in conjunction with the auditedfinancial statements and notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31,2024, as filed with the Securities and Exchange Commission on February 28, 2025, from which we derived ourbalance sheet as of December 31, 2024. The accompanying unaudited condensed financial statements have beenprepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financialinformation